基因修饰小鼠模型为前列腺癌去势抵抗治疗的耐药机制研究带来曙光。
GEMMs shine a light on resistance to androgen deprivation therapy for prostate cancer.
机构信息
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
出版信息
Cancer Cell. 2013 Jul 8;24(1):11-3. doi: 10.1016/j.ccr.2013.06.007.
Abstract
Androgen deprivation therapy (ADT) for advanced prostate cancer inexorably leads to resistance, and clinically useful biomarkers are lacking. The value of genetically engineered mice for coclinical studies is clearly demonstrated in a recent publication that reveals XAF1, XIAP, and SRD5A1 as novel predictive biomarkers and therapeutic targets for ADT resistance.
摘要
雄激素剥夺疗法（ADT）治疗晚期前列腺癌不可避免地会导致耐药，而目前缺乏临床有用的生物标志物。最近的一篇出版物清楚地证明了基因工程小鼠在临床前研究中的价值，该研究揭示了 XAF1、XIAP 和 SRD5A1 是 ADT 耐药的新的预测性生物标志物和治疗靶点。
Zotero 插件